Awaiting development: Guidance and quality standards

Showing 161 to 170 of 307

Guidance and quality standards awaiting development
Title	Type
Mozafancogene autotemcel for treating Fanconi anaemia in people 1 to 17 years [ID12203]	Technology appraisal guidance
Nedosiran treating primary hyperoxaluria type 1 in people 6 years and over [TSID11777]	Technology appraisal guidance
Netarsudil for treating open angle glaucoma or ocular hypertension [ID1078]	Technology appraisal guidance
Nicardipine (Nicaplant) for aneurysmal subarachnoid haemorrhage patients undergoing aneurysm clipping [TSID10593]	Technology appraisal guidance
Nipocalimab for treating generalised myasthenia gravis [ID6562]	Technology appraisal guidance
Niraparib with abiraterone acetate and prednisone for treating hormone-sensitive metastatic prostate cancer [ID6595]	Technology appraisal guidance
Nivolumab with ipilimumab for adjuvant treatment of localised renal cell carcinoma [TSID9659]	Technology appraisal guidance
Norucholic acid for treating primary sclerosing cholangitis [ID6583]	Technology appraisal guidance
Obicetrapib or obicetrapib–ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia [ID6519]	Technology appraisal guidance
Odevixibat for treating biliary atresia in children following Kasai hepatoportoenterostomy [ID6627]	Technology appraisal guidance